222 Users Online
Transforming Growth Factor Market Segmented By Activin, Bone Morphogenetic Proteins, TGF-beta Proteins Product with GMP Grade and NON-GMP Grade
The global revenue from the transforming growth factor market stands at US$ 362.7 Mn in 2022, with the global market expected to grow at a CAGR of 7.4% to reach a valuation of approximately US$ 798.2 Mn by the end of 2033.
| Attributes | Key Insights |
|---|---|
|
Market Size (2022) |
US$ 362.7 Mn |
|
Projected Market Value (2033) |
US$ 798.2 Mn |
|
Global Market Growth Rate (2023-2033) |
7.4% CAGR |
|
Market Share of Top 5 Countries |
63.2% |
As assessed by Persistence Market Research, non-GMP grade products are expected to hold a market value of around US$ 515.2 Mn by 2033. Overall, transforming growth factor market sales account for approximately 20.2% revenue share in the global growth factors market, which was valued at around US$ 1.8 Bn in 2022.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The global market recorded a historic CAGR of 6.5% in the last 6 years from 2016 to 2022.
Transforming growth factor (TGF) influences embryogenesis, wound healing, fibrosis, inflammation, and tumour growth by taking part in a number of cellular processes such differentiation, multiplication, migration, extracellular matrix (ECM) remodelling, and apoptosis.
Fibrotic reactions that are physiologic or pathologic can have an impact on any organ in the body. Under homeostatic settings, these reactions are self-contained and repair damage to wounded tissues, a process vital to health and survival. However, in fibrotic disorders, an unchecked fibrotic process results in an abnormal accumulation of ECM, particularly proteoglycans, hyaluronic acid, fibronectin, and collagen, which finally causes organ failure. This happens under chronic and persistent pathologic conditions.
Healing from chronic wounds takes time. TGF are essential for promoting the development of granulation tissue, controlling inflammatory reactions, and triggering angiogenesis.
They are crucial to the development and remodelling of the matrix during the course of the typical wound healing process. Acute wounds, chronic cutaneous ulcers, and pressure ulcers all exhibit growth factor deficit.
Currently, topical growth factor treatment is a promising wound healing technique. Researchers are concentrating on the development of new solutions to get beyond the limits of single growth factor-based products because each stage of healing requires a distinct combination of certain cytokines and growth factors.
Expanding investigation in the areas of skin regeneration and wound healing is anticipated to help the global market develop.
The global market is thus likely to show high growth over the coming years at a CAGR of 7.4% and reach a global market size of US$ 798.2 Mn by 2033.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version“Specialty Products and Shift to Asia Pacific Markets”
There are just a few businesses that are solely focused on being a supplier of GMP-grade products and reagents, despite the market having a number of large and countless smaller businesses. Diverse manufacturers have different specialties and product offerings, with the majority of major companies integrating products and services, biologics, recombinant proteins, and consumables with technology, in-vitro diagnostics tools, and many others.
Focusing solely on this market assures higher product quality, repeat business from clients, and a well-established distribution network to ensure product availability all over the world. The life sciences industry has one of the highest R&D spending levels across all industries, and during the coming years, spending is anticipated to increase steadily.
Investment in R&D and technology, particularly in the bio sciences, has shifted away from North America and Europe and into Asia Pacific. The potential for outsourcing biotech projects is increased by the availability of skilled labour and qualified workforce in developing economies like India at reasonable prices.
Additionally, governments in the Asia Pacific region have begun to take action to encourage the development of the regional biotechnology industry by providing tax exemptions for R&D, raising budgets and funding, establishing public and private corporations, and luring foreign direct investments.
“Lack of Skilled Professionals, and High Cost of Products”
The development of novel, high - cost products has been prompted by the life sciences community's researchers' increasingly complex requirements. Many consumers are hesitant to spend money on such pricey products due to the uncertainty of the outcomes anticipated from extensive research studies, particularly for research teams with budget constraints and financing.
Certain growth factors are highly expensive. For the majority of laboratories, this is a constraint. Most of the major vendors of research items have catalogues, but customized research services and products are typically several times more expensive than those products. However, because premium products and services are superior to standard reagents and consumables, there is a growing trend towards endorsing them.
By producing new information about the importance, competent professionals can support progress and innovation in research and development. Unfortunately, there is a lack of qualified individuals working in research and development in the market.
Some of the main causes of a shortage of qualified professionals are low pay scales, arduous duties, and insufficient laboratory training. Skilled personnel are required to oversee research and development based on biologics, growth factors, and cell culture.
As a result, the global market may experience slow growth due to a lack of experienced individuals and a shortage of equipment and other accessories related to research facilities.
Sales Team
Client Partner
Why is the U.S. Market Booming?
“Technological Advancements and Introduction of Personalized Pharmaceuticals”
The U.S. accounted for around 94.1% market share in the North America market in 2022. Growing capital expenditure on the manufacturing of pharmaceutical products and rising number of established manufacturers within the region have propelled market sales within the U.S. Moreover, with the advent of commercialization of customized pharmaceutical products, as well as rising efforts in the research and development of novel biologics, the market in the country is expected to expand at a lucrative pace over the forecast period.
Will Germany Be a Lucrative Market for Transforming Growth Factor?
“Presence of Established Manufacturers”
Germany held around 28.2% market share of the Europe market in 2022. The cost of healthcare per person is consistently rising worldwide. Healthcare spending has changed significantly as a result of people's willingness and ability to spend on their health and wellness.
Furthermore, the country's availability is improved by the presence of production facilities for growth factor products. Additionally, major firms are engaging in mergers and acquisitions to expand their product portfolios in order to capitalise on growth factors.
How is China Emerging as a Prominent Market?
“Growing Economy and Rising CMO Activities”
China held the largest market share of about 46.8% of the East Asia market in 2022. Economic, social, and environmental imbalances have resulted from China's strong growth that was mostly limited by low-cost manufacturing, exports, and investment.
Changes in the economy's structure-from production to high profit services, from invested capital to usage, as well as from higher concentration to a lower carbon intensity, have been crucial to minimize these imbalances. Large number of CRO and CMO activities within the country have further been supported by these mentioned factors, thus propelling the overall market sales within China.
Which Product is Driving Demand within the Global Market?
“Studies on the Role of BMPs throughout Cellular Development”
The bone morphogenetic proteins (BMPs) segment held around 43.6% share of the global market in 2022. Originally recognised as osteoinductive elements in bone extracts, bone morphogenetic proteins (BMPs) are now understood to play crucial roles in a variety of processes during the development and upkeep of many organs, including kidney, muscle, blood vessels, cartilage, and bone.
The regulation of cellular differentiation, apoptosis, lineage commitment, proliferation, and morphogenesis of different types of cells in the human body by the bone morphogenetic protein (BMP) family of ligands plays important roles in a variety of processes during adult homeostasis and embryonic development, making it a prime segment for consideration within the market scope.
Which Grade of Manufacturing is Largely in Focus Globally?
“Expanding Production Facilities and Rising Research Activities”
The non-GMP grade segment held market share of around 69.7% in 2022. Non-GMP grade products hold a larger share, primarily due to increasing focus on development and research in oncology, and increasing number of contract research organizational activities.
With the production of non-GMP grade goods, several manufacturers have been able to increase their pharmaceutical production facilities. Moreover, the cost constraints during the production process are reduced, thus propelling this segment within the global market.
Which Application within the Market Displays Greater Adoption?
“Relevance of TGF in Cancer Progression”
Cell therapy and Ex vivo manufacturing leads the market with a share of around 28.8% in 2022. It is known that multiple functions of TGF-beta are involved in the development of malignancies. It has a strong inhibitory effect on the proliferation of epithelial, hematopoietic, and stromal cells. However, the majority of altered cells eventually develop partial or complete resistance to TGF-beta growth inhibition during the course of cancer progression.
Given the growing prevalence of chronic disease, as well as the high global burden of cancer, the segment holds greater share in terms of demand within the global market.
Which End User Offers the Market a Profitable Outlook?
“High Global Burden of Disease Prompting Larger Production and Manufacturing”
Pharmaceutical and biotechnology companies hold a larger share of about 47.7% with a market value of around US$ 172.9 Mn in 2022. Owed to the large demand from the global market for novel pharmaceutical solutions due to the large volumes of diseased population, pharmaceutical and biotechnology companies are investing greatly in their research and production units.
Moreover, the worldwide trend of introducing major production and manufacturing to contract manufacturing organizations in the Asia Pacific regions has further propelled the growth of this segment within the global market.
Manufacturers frequently use acquisitions, mergers, expansions, and launches to boost sales in various geographies. In order to diversify their product offering and seize market share in emerging economies, the corporations are concentrating their R&D efforts in the Asia Pacific region.
Additionally, companies are enhancing their product portfolio via new product lines and R&D expenditures. Manufacturers have made significant investments in R&D to diversify their product offerings and increase their market share globally, particularly to meet the changing demands of researchers.
Some key instances of development include:
| Attribute | Details |
|---|---|
|
Forecast Period |
2023-2033 |
|
Historical Data Available for |
2016-2022 |
|
Market Analysis |
USD Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Product:
Grade:
Application:
End User:
Region:
The global market is currently valued at around US$ 362.7 Mn in 2022.
Sales of the market are set to witness a high growth at a CAGR of 7.4% and be valued at around US$ 798.2 Mn by 2033.
Demand for the global market increased at a 6.5% CAGR from 2016 to 2022.
U.S., Germany, UK, China, and France account for most demand within the market, currently holding around 63.2% market share.
The U.S. accounts for around 94.1% share of the North American market in 2022.
Latin America accounts for around 4.7% share of the global market in 2022.
China market held a share of about 46.8% in the East Asia transforming growth factor market in 2022.
Germany held around 28.2% market share of the Europe market in 2022.
Brazil transforming growth factor market is expected to grow at a 6.6% CAGR during the forecast period.
The transforming growth factor market in India is set to expand at a 10.8% CAGR over the forecast period.
